Insight

The use of surrogate endpoints in solid and haematological cancers

Photo from Timothée Olivier/X

Oct 8, 2024, 13:20

The use of surrogate endpoints in solid and haematological cancers

Ash Paul, Medical Director at EoE Specialised Commissioning Group, UK, shared a post on X:

“Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more.”

Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more

Authors: Timothée Olivier, Alyson Haslam, Dagney Ochoa, Eduardo Fernandez and Vinay Prasad.

Source: Ash Paul/X

Alyson Haslam Ash Paul cancer cancer awareness cancer care Dagney Ochoa Eduardo Fernandez fight against cancer Global fight against cancer haematological cancers OncoDaily Oncology Timothée Olivier Vinay Prasad

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Special Coverage